Alterations in Respiratory Function Test Three Months after Hospitalisation for COVID-19 Pneumonia: Value of Determining Nitric Oxide Diffusion

Abstract

Three to four months after hospitalisation for COVID-19 pneumonia, the most frequently described alteration in respiratory function tests (RFTs) is decreased carbon monoxide transfer capacity (DLCO). Methods: This is a prospective cohort study that included patients hospitalised because of SARS-CoV-2 pneumonia, three months after their discharge. A clinical evaluation, analytical parameters, chest X-ray, six-minute walk test, spirometry and DLCO–DLNO analysis were performed. Demographic variables, comorbidities, and variables related to the severity of the admission were recorded. Results: Two hundred patients completed the study; 59.5% men, age 62 years, 15.5% admitted to the intensive care unit. The most frequent functional alteration, in 27% of patients, was in the DLCO–DLNO combination. This alteration was associated with age, male sex, degree of dyspnoea, poorer perception of health, and limited ability for physical effort. These patients also presented higher levels of D-Dimer and more residual radiological alterations. In 42% of the patients with diffusion alterations, only reduced DLNO was presented, along with lower D-Dimer levels and less capillary volume involvement. The severity of the process was associated with the reduction in DLCO–DLNO. Conclusions: The most sensitive RFT for the detection of the sequelae of COVID-19 pneumonia was the combined measurement of DLCO–DLNO and this factor was related to patient health status and their capacity for physical exertion. In 40% of these cases, there was only a reduction in DLNO, a finding that may indicate less pulmonary vascular involvement.

Serum nitrite and nitrate: A potential biomarker for post-covid-19 complications?

“…One recent study reported decreased total NO, nitrite and SNO in COVID-19 patients in hospital [ 36 ]. Another study in Spain showed that nitric oxide diffusion was reduced in around 40% patients discharged from hospital, via respiratory function tests with a MasterScreen PFT equipment [ 37 ]. To date, the levels of NO in blood among patients discharged from hospitals, i.e.…”

Therapeutic Effects of Inhaled Nitric Oxide Therapy in COVID-19 Patients

“…In systemic endothelial dysfunction, the deficiency of the synthase-dependent pathway of NO generation can be corrected by its exogenous supplementation. Recent studies reported a decreased total NO and its metabolites in hospitalized COVID-19 patients, as well as a decreased nitric oxide diffusion in around 40% of patients discharged from the hospital [ 154 , 155 ]. Other authors claim that reduced concentrations of NO metabolites may be potential biomarkers of long-term poor or irreversible outcomes after a SARS-CoV-2 infection and might serve as a predictor to track the health status of recovered COVID-19 patients [ 156 ].…”

Recent Advances in Phthalocyanine and Porphyrin-Based Materials as Active Layers for Nitric Oxide Chemical Sensors

“…It has been shown that an increase in the concentration of fractional exhaled nitric oxide (FENO) indicated some diseases of the respiratory tract, such as asthma [ 7 , 8 , 12 , 13 ], allergy [ 9 , 14 , 15 ] and chronic cough [ 10 , 16 ]. Moreover, in connection with the COVID-19 pandemics, scientists have begun to publish works in which the analysis of the nitric oxide concentration could be useful for the diagnostics of coronavirus disease [ 17 , 18 ]. Several sensor devices have already been produced for the detection of FENO [ 19 ].…”